Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs.
about
Neurobiologic Advances from the Brain Disease Model of AddictionMedications for unhealthy alcohol use: across the spectrum.Serial longitudinal magnetic resonance imaging data indicate non-linear regional gray matter volume recovery in abstinent alcohol-dependent individuals.Gay/Lesbian sexual orientation increases risk for cigarette smoking and heavy drinking among members of a large Northern California health plan.Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model.Associations between Korean Adolescents' Sexual Orientation and Suicidal Ideation, Plans, Attempts, and Medically Serious Attempts.Brief Alcohol Intervention Among At-Risk Drinkers with Diabetes.Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence.Intervention to reduce excessive alcohol consumption and improve comorbidity outcomes in hypertensive or depressed primary care patients: two parallel cluster randomized feasibility trials.Cost of Care for HIV-Infected Patients with Co-Occurring Substance Use Disorder or Psychiatric Disease: Report from a Large, Integrated Health PlanBrain-derived neurotrophic factor genotype is associated with brain gray and white matter tissue volumes recovery in abstinent alcohol-dependent individualsFrequency of 5+/4+ drinks as a screener for drug use and drug-use disorders.MRSI and DTI: a multimodal approach for improved detection of white matter abnormalities in alcohol and nicotine dependenceChronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system.Screening and brief intervention for unhealthy drug use in primary care settings: randomized clinical trials are needed.Alcohol and sleep problems in primary care patients: a report from the AAFP National Research Network.Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients.Medical Conditions of Hazardous Drinkers and Drug Users in Primary Care Clinics in Cape Town, South AfricaConducting record review studies in clinical practice.Cortical perfusion in alcohol-dependent individuals during short-term abstinence: relationships to resumption of hazardous drinking after treatmentEffects of cigarette smoking history on neurocognitive recovery over 8 months of abstinence in alcohol-dependent individualsSubdiagnostic alcohol use by depressed men and women seeking outpatient psychiatric services: consumption patterns and motivation to reduce drinking.Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months laterAlcohol screening and changes in problem drinking behaviors in medical care settings: a longitudinal perspectiveCortical thickness, surface area, and volume of the brain reward system in alcohol dependence: relationships to relapse and extended abstinence.Alcohol use disorder with and without stimulant use: brain morphometry and its associations with cigarette smoking, cognition, and inhibitory control.Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program.A comprehensive assessment of neurocognition in middle-aged chronic cigarette smokers.Screening, Brief Intervention, Referral to Treatment (SBIRT), and Motivational Interviewing for PGY-1 Medical Residents.Equipping Residents to Address Alcohol and Drug Abuse: The National SBIRT Residency Training Project.Association Between Receipt of Brief Alcohol Intervention and Quality of Care among Veteran Outpatients with Unhealthy Alcohol UseGlutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changesProspective changes in alcohol use among hazardous drinkers in the absence of treatment.Physician versus non-physician delivery of alcohol screening, brief intervention and referral to treatment in adult primary care: the ADVISe cluster randomized controlled implementation trialPolysubstance and alcohol dependence: unique abnormalities of magnetic resonance-derived brain metabolite levelsExamining multi-session brief intervention for substance use in primary care: research methods of a randomized controlled trial.The relationships of sociodemographic factors, medical, psychiatric, and substance-misuse co-morbidities to neurocognition in short-term abstinent alcohol-dependent individuals.The influence of chronic cigarette smoking on neurocognitive recovery after mild traumatic brain injury.Substance use among persons with homeless experience in primary care.Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation
P2860
Q26774129-6A767133-526C-4F67-8C3F-FABC49EC6FDDQ27690692-FED4C169-3021-4A11-AFB4-C4739E6A90DEQ30846460-FB30D44A-ED97-4247-BC7D-0927E45CFC3DQ33259246-5F37F733-CDF1-4F1B-9DA0-45B08FF6C875Q33441704-4A53F9D7-C0AB-4D65-B91F-0F4ED461345FQ33711058-DFAB337C-88B9-49A9-BAA9-553745F2C755Q33737880-64A7339A-26B3-494F-A455-4725DB9BAD17Q33739510-DB5AA8CD-E38A-4878-9C6D-4D72853B7409Q33825718-5C18FF80-11FD-4BA0-8FFA-4DEBB024300DQ33876681-09B1888C-AFF3-4AE1-A872-F48CDED27B1CQ34075816-15B86997-E13B-4FAA-ACE8-416D5C1E1115Q34093475-88DA0B28-DCA6-416A-8FB7-9B36115A6B25Q34143071-5498C997-EDC9-4C0E-83D5-94EE434A418CQ34148796-279E40E3-3912-46DE-9C45-989571C2644FQ34177139-32652472-316D-41EA-9B41-6FD91F36876BQ34287646-43F88E23-51F3-499A-BEC7-10065673299EQ34365075-133E06C4-8B3D-4A7C-AE4E-DF98825123F9Q34445333-09F7BA19-45AA-4715-AAA9-AF19EC136AFFQ34479772-5C829601-AFB6-4317-BA81-4EE6D851E8A2Q34572465-BC289AA9-DEFE-4898-B090-A5A1A1DDAC46Q34577199-29D9A992-2919-4450-AA2C-E91DCE5F2A31Q34733631-59F34C0F-22D9-407A-8457-2A516F6979FCQ34859268-A5672F1C-692B-476E-B991-1DC2C30A1BCCQ34884143-CB8192BF-CEF7-4E9C-ABC1-8FB498377195Q34990385-307FAADC-DD38-4929-8186-93F577FCA1BAQ35214365-E8DDBA89-A490-4E6F-993E-025E6662517FQ35623599-701313CA-4EF6-4C3C-B4DA-8AD1E2A569A5Q35673184-38EB864D-4A00-49FC-969A-2D7F17E4507EQ35770404-234D7F1D-77BA-4F7E-BD47-7F85B9BC81A8Q35853376-88AD463B-23B5-4EEB-930C-9ED9E28F9A8BQ35876687-52CF9090-CAC2-4150-A0D7-C60F49044CA1Q36164790-0D521480-DCAE-4000-8D67-14FE5A848114Q36188207-040437FD-12E1-48C2-BE2F-5EA92A0DBCBDQ36301995-C39E3288-EBA8-4779-A80E-CCFDF53B68C0Q36759409-159C87F2-2447-43AA-8B56-E0B22156D9BDQ36810572-A86E8DFE-2B2E-4EB3-A7A7-335BF9145EB4Q37003483-30A66C51-1FBA-4D4D-B5FD-E9AE0BCC787DQ37107765-3FED63E9-7722-40EC-8491-291EAF095B94Q37207837-78DC221B-2090-4B6D-96BC-25CD9D309A7AQ37296166-5E3C6BCA-0BE2-4405-AA3B-6E282AA0805A
P2860
Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Hazardous drinkers and drug us ...... medical conditions, and costs.
@ast
Hazardous drinkers and drug us ...... medical conditions, and costs.
@en
Hazardous drinkers and drug us ...... medical conditions, and costs.
@nl
type
label
Hazardous drinkers and drug us ...... medical conditions, and costs.
@ast
Hazardous drinkers and drug us ...... medical conditions, and costs.
@en
Hazardous drinkers and drug us ...... medical conditions, and costs.
@nl
prefLabel
Hazardous drinkers and drug us ...... medical conditions, and costs.
@ast
Hazardous drinkers and drug us ...... medical conditions, and costs.
@en
Hazardous drinkers and drug us ...... medical conditions, and costs.
@nl
P2093
P2860
P1476
Hazardous drinkers and drug us ...... medical conditions, and costs.
@en
P2093
Bruce Fireman
Constance Weisner
G Thomas Ray
Jennifer R Mertens
Kevin Walsh
P2860
P304
P356
10.1097/01.ALC.0000167958.68586.3D
P577
2005-06-01T00:00:00Z